Versantis locks in Series B

Versantis, a Swiss developer of therapies for rare liver and pediatric diseases, has raised CHF 16 million Series B in financing. Swisscanto Invest by Zürcher Kantonalbank led the round with participation from Esperante Ventures, investiere, Redalpine HealthEquity and Zürcher Kantonalbank Start-up Finance.

North AmericaUSHealthcareBriefs